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Abstract
Aims To compare current General Medical Practitioner treatment as usual (TAU) for the treatment of female urinary incon-
tinence with a novel disposable home electro-stimulation device (Pelviva).
Methods Open label, Primary Care post-market evaluation. 86 women with urinary incontinence were randomly assigned to 
one of two 12-week treatments: TAU or Pelviva for 30 min every other day plus TAU. Outcome measures included ICIQ-UI 
(primary), PISQ-IR, PGI-S / PGI-I and FSFI (secondary) at recruitment and immediately after intervention, 1-h pad test at 
recruitment and usage diaries throughout.
Results Pelviva plus TAU produced significantly better outcome than TAU alone: 3 versus 1 point for ICIQ-UI (Difference 
− 1.8 95% CI: − 3.5 to − 0.1, P = 0.033). Significant differences were also observed for PGI-I at both 6 weeks (P = 0.001) 
and 12 weeks (P < 0.001). In the Pelviva group, 17% of women described themselves as feeling very much better and 54% a 
little or much better compared to 0% and 15% in the TAU. Overall PISQ-IR score reached statistical significance (P = 0.032) 
seemingly related to impact (P = 0.027). No other outcome measures reached statistical significance. Premature termination 
due to COVID-19 meant only 86 women were recruited from a sample size of 264. TAU did not reflect NICE guidelines.
Conclusions This study suggests Pelviva is more successful than TAU in treating urinary incontinence in Primary Care. The 
study had reduced power due to early termination due to COVID-19 and suggests TAU does not follow NICE guidelines.
Keywords Electrostimulation device · Female urinary incontinence · Pelvic floor muscle · Randomised Controlled Trial · 
Rehabilitation
Introduction
Bladder problems affect millions of people worldwide with 
25–45% of women reporting some degree of urinary incon-
tinence [1]. The impact can be considerable and distressing, 
affecting both quality of life and sexual function [2].
The most common types of incontinence in women are 
stress, urgency and mixed [3]. Stress urinary incontinence 
(SUI) is associated with leakage of urine during activities 
that increase intra-abdominal pressure (physical exertion, 
coughing, or sneezing). Urgency urinary incontinence (UUI) 
is associated with urgency, frequency or being woken at 
night to pass urine. Stress and urgency incontinence together 
is classified as mixed urinary incontinence (MUI).
Most conservative treatments target pelvic floor muscle 
function and include biofeedback, weighted cones and pelvic 
floor muscle exercises. Voluntary contraction of the pelvic 
floor is, however, fraught with difficulties with as many as 
50% of women unable to correctly perform an unsupervised 
contraction [4–6].
NICE 2019 guidance recommend 3 months of supervised 
pelvic floor muscle exercises. However, urinary incontinence 
is a stigmatizing condition [7] and women do not tend to 
seek help [8], leaving them with little option other than to 
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self-manage their problem. This highlights the importance 
of evidence-based self-management treatment options.
Pelviva is a commercially available single use, disposable 
Pelvic Floor muscle trainer, manufactured from compress-
ible foam and is inserted like a tampon into the vagina and 
removed using a pull cord. It delivers effective stimulation 
to the pelvic floor muscles, eliciting a contraction as per 
the stimulation protocol described by Oldham et al. [9]. In 
a previous randomised controlled trial, Pelviva plus pelvic 
floor muscle exercise demonstrated a statistically significant 
(P = 0.014) improvement in quality of life as measured by 
the International Consultation on Incontinence Question-
naire – Urinary Incontinence Short Form (ICIQ-UI SF) com-
pared to pelvic floor exercises alone in the treatment of all 
types of incontinence in women [9].
Aims of the study
The trial by Oldham et al. in 2013 [9] was undertaken in 
a strict laboratory, highly controlled research environment 
and did not reflect the real world situation but suggested that 
Pelviva could offer an effective solution to the management 
urinary incontinence in Primary Care. This pragmatic trial 
was designed therefore to test the effectiveness of Pelviva in 
a real-world situation and to compare Pelviva with current 
General Medical Practitioner (GP) treatment for the manage-
ment of female urinary incontinence.
Primary hypothesis
A novel disposable home electro-stimulation device (Pel-
viva) is more effective than General Medical Practitioner 
treatment for female urinary incontinence in terms of fre-
quency of urinary incontinence, amount of leakage and 
overall impact of urinary incontinence as measured by the 
ICIQ-UI SF.
Materials and methods
An open-label, community-based, post-market, randomised 
controlled trial of a novel neuromuscular electrical stimula-
tion treatment for urinary incontinence (Pelviva) was under-
taken. Women with urinary incontinence (urgency, stress or 
mixed), determined through consultation with their General 
Medical Practitioner (GP), were randomised into one of two 
groups. The treatment as usual control group (TAU) received 
routine care, following each GP’s standard practice, for their 
urinary incontinence determined by their GP and may have 
included Pelvic floor exercises explained by the doctor/prac-
tice nurse; weighted exercise cones; pelvic toner device; vag-
inal insert device e.g. Contiform; pelvic floor physiotherapy; 
bladder re-training (Continence service); medication which 
could include anticholinergics or mirabegron. The interven-
tion group received the Pelviva device in addition to active 
TAU. Treatment lasted for 12 weeks with a Quality of Life 
(QoL) primary end point immediately post-treatment.
Participants and recruitment
Women aged between 18 and 65 years were recruited from 
practices within the South Manchester GP Federation. Sub-
jects were identified by electronic health record searches 
(diagnosis, prescribed medication, treatment), contacted by 
text message from GPs and practice nurses and screened for 
eligibility by GPs.
Affirmative responders were sent a letter, including a 
participant information leaflet and sample consent form, 
followed by a telephone call inviting them to participate 
in the study. At the initial visit, women were individually 
consented and eligibility for participation in the study estab-
lished. All participants were able to withdraw from the study 
via telephone, email or post at any time. All withdrawals 
were recorded electronically.
Approvals and trial registration
Ethical approval was granted by Greater Manchester South 
Research Ethics Committee (REC Reference 17/NW/0395). 
MHRA approval was granted in 2009 (CI/2009/0008). Trial 
registration ClinicalTrials.gov identifier: NCT04059653.
Inclusion and exclusion criteria
Inclusion criteria were women aged between 18 and 65, GP 
established urinary incontinence and willingness to partici-
pate in the study. GP determined exclusion criteria were: 
abnormal abdominal mass; clinical history of urinary reten-
tion problems: severe atrophic vaginitis, vaginal infection, 
vaginal lesion, severe urogenital prolapse at the level of the 
vaginal introitus or any other pathology of the vagina or 
labia; pregnancy or given birth within the last 3 months; 
implanted pacemaker; recent pelvic surgery (within the last 
12 months); recent haemorrhage, haematoma and/or tissue 
damage to the vagina; undergoing any active therapy or 
review appointments for pelvic malignancy; manual dex-
terity insufficient to place the Pelviva device in the vagina; 
presence of a severe neurological conditions such as Mul-
tiple Sclerosis, Motor Neuron Disease or Parkinson’s Dis-
ease; multiple co-morbidities to the extent that the activi-
ties involved in the ‘pad test’ (i.e. stair climbing) cannot be 
completed; insufficient cognitive ability to provide informed 
consent and/or participate in the study. Any evidence of a 
urinary tract infection was confirmed by urinary dip stick 
test, with women treated accordingly and free of infection 
before being eligible to participate in the trial.
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Randomisation and blinding
Immediately after baseline assessment an online randomisa-
tion service (www. seale denve lope. com) was accessed by the 
research team to assign women to either the Pelviva or TAU 
group utilising random permuted blocks with block sizes of 
4–8. Participants could not be blinded to the treatment and 
were aware of the two potential treatment groups. The trial 
management, oversight and analysis team remained blinded 
to treatment allocation until after data lock.
Intervention protocols
Control
As this trial was designed as a real world study the TAU 
group treatment was not pre-defined. As such, this could 
comprise of any of the treatments recommended in the NICE 
Clinical Guideline 123 [10], with the GPs free to select the 
most appropriate treatment for their patient including contin-
uation of any medication that had already been prescribed.
Pelviva group
The Pelviva group continued with any existing prescribed 
GP care and in addition were prescribed a 12-week course 
of Pelviva treatment. Pelviva is a commercially available, 
single use disposable, fully automated, neuromuscular elec-
trical stimulation device which is used every other day for 
30 min. For further details, refer to Oldham et al. [9]. Any 
queries regarding use of the device were managed via tel-
ephone and email.
The stimulation programme was delivered using a duty 
cycle of 10-s stimulation followed by 10-s rest that runs for a 
period of 30 min. The Pelviva devices were pre-programmed 
to automatically gradually ramp-up the intensity of stimu-
lation over a 24-s period to reach a therapeutic level and 
switch off automatically after 30 min. All devices were pro-
grammed to supply the same level of stimulation namely the 
average intensity that is considered comfortable and capable 
of producing a contraction of the pelvic floor muscles. This 
was determined through pilot safety and evaluation stud-
ies conducted in accordance with International Standards 
Organisation (ISO) 14,155. During the 10-s ‘‘on time’’, the 
device delivered a patent protected ten repeats of a short 
high-intensity burst of 50 Hz stimulation immediately pre-
ceded by a doublet (125 Hz), superimposed on continuous 
low-frequency 2-Hz stimulation. The devices will have an 
associated purchasing cost but it is envisaged this will be off-




The primary outcome measure was the self-completed short 
form version of the International Consultation on Inconti-
nence Questionnaire—Urinary Incontinence (ICIQ-UI-SF) 
[11]. Question items included frequency of urinary inconti-
nence, amount of leakage, overall impact of urinary inconti-
nence and an unscored self-diagnostic item. The 0–21 over-
all score (greater values indicating increased severity) was 
defined as the primary outcome. A clinically meaningful 
difference is described as a reduction of 2 or more points 
[11]. Subscales were specified as secondary outcomes.
Secondary outcomes
The secondary outcomes were included to assess the effects 
on sexual health, patient reported assessment of severity and 
improvement of their condition and an objective measure of 
amount of urine lost. These were assessment by utilisation 
of:
• The International Urogynaecology Association (IUGA) 
Pelvic Organ Prolapse/Urinary Incontinence Sexual 
Questionnaire (PISQ-IR) for evaluation of sexual dys-
function [12].
• The Patient Global Impression of Severity (PGI-S) and of 
Improvement (PGI-I) questionnaire for global assessment 
of improvement in incontinence [13].
• The Female Sexual Function Index (FSFI)—to assess 
impact on domains of sexual functioning (e.g. sexual 
arousal, orgasm, satisfaction, pain) [14].
• A 1-h in-clinic provocative pad weight test “1-h pad test” 
as defined by the International Continence Society (ICS) 
[15].
All questionnaires were collected immediately pre-treat-
ment (at baseline), mid-treatment (at 6 weeks) and end of 
treatment (at 12 weeks). The 1-h pad test was planned at 
baseline and end of treatment but only completed at baseline 
due to COVID-19 restrictions.
Participants were also requested to complete diaries every 
other day for 4 weeks of the trial and then every week for the 
following 8 weeks to record treatment usage and usability 
specific to treatment arm.
Data for all questionnaires were collected electronically 
using a secure electronic data capture system Red Pill (https:// 
www. seale denve lope. com/ redpi ll/). The system reminded 
participants to complete the questionnaire data in the privacy 
of their own home via mobile phone, tablet or computer and 
sent reminders for overdue questionnaires. Research nurses 
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telephoned participants if multiple questionnaires or diaries 
were missing. Other case report form data (e.g. pad-test, eligi-
bility criteria, urinalysis tests) were entered online by research 
nurses (Red Pill ePRO).
Sample size
This study was initially powered to detect a 1.5-point mean 
difference (considered to be clinically meaningful) between 
groups in terms of quality of life immediately post-treatment 
as measured by the ICIQ-UI with conservative SD estimate 
of 3.75 based on a previous trial [9]. A sample size of 132 per 
group was determined (two-sided test, with 0.05 level of sig-
nificance and 90% power). However, the study was terminated 
prematurely due to COVID-19 restrictions and this number 
was not achieved.
Statistical analysis
The analysis was pre-specified in a Statistical Analysis Plan 
finalised prior to database lock and the unbinding of the Trial 
Statistician and Management Team.
Adherence to the active treatment was assessed by sum-
ming the patient reported number of devices used in each diary 
period, censoring the few that reported more devices used than 
prescribed at 100% and expressing this as a proportion of the 
number prescribed. As diary completion was incomplete, a 
second estimate conservatively assumed that missing diaries 
represented no usage. The analysis dataset included all women 
randomised who provided data for the primary outcome.
The primary analyses utilised standard analysis of covari-
ance models adjusting for baseline and type of incontinence. 
Baseline, follow-up and within-patient changes were com-
puted and summarised to aid interpretation. The four-point 
PGI-severity scale was dichotomised into normal/mild and 
moderate/severe and analysed using analogous logistic regres-
sion models. The ordinal PIG-I improvement measure was 
only meaningful at follow-up and the treatment arms were 
compared using a Mann–Whitney U test. All analyses were 
conducted in the R statistical environment with R-markdown 
scripts.
Results
COVID-19 pandemic restrictions prevented face-to-face con-
tact at the 12-week follow-up and the pad test could only be 
completed at baseline. Restrictions also led to premature clo-
sure of the trial and impacted the intention to undertake follow-
up assessments annually for 3 years.
The Consolidating Standards of Reporting Clinical Trials 
(CONSORT) diagram (Fig. 1) shows over a 12-week period 
226 women responded to a total of 13,052 text messages 
(1.7%). Of these women, 108 could not be contacted and 4 
withdrew before randomisation. A further 28 women were 
screened and found ineligible according to exclusion criteria.
Patient characteristics are summarised in Table 1. The 
majority of women had stress or mixed urinary incontinence, 
with only one describing standalone urgency. The majority 
of women (70%) demonstrated mild incontinence determined 
by urine loss on 1-h pad test as 10 g or less, 23% moderate 
between 10.1 and 50 g and 7% severe greater than 50 g loss.
At baseline 67% in the active TAU control group and 71% 
in the Pelviva group described no treatment for their inconti-
nence. During the trial, the TAU group reported 31% receiving 
no active treatment compared to 68% in the Pelviva group. Of 
note 64% of women in the TAU group reported now doing 
unsupervised pelvic floor exercises, this increase was not 
observed in the Pelviva group.
Adherence to the Pelviva treatment was 78% based on the 
completed diary entries (devices used/devices prescribed). Not 
everyone fully completed the diary entries and if uncompleted 
dairies are conservatively assumed to represent no device 
usage, adherence was still 61%.
Primary outcome: quality of life
Results of the ICIQ-UI are summarised in Table 2 and Fig. 2.
After 12 weeks of treatment the Pelviva women showed 
a mean 3-point improvement compared to a mean < 1-point 
improvement for the control group on the 21-point scale, with 
an overall treatment effect of − 1.81 points (95% CI: − 3.49 to 
− 0.14, P = 0.033). There were no significant between group 
differences for frequency, amount and interference subscales, 
although the estimates of all the subscales did point to an 
improvement.
Improvements in overall ICIQ-UI were evident at 6 weeks 
with the Pelviva group with the treatment effect estimated as 
− 1.04 points (95% CI − 2.18 to − 0.10, P = 0.072).
Secondary outcomes
Patient global assessment of severity and improvement
Given the early closure of the trial, there was little statisti-
cal power to detect changes in PGI-severity with the OR 
for moderate/severe symptoms being 0.5 (95% CI 0.1–1.6), 
With the OR for moderate/severe symptoms being 0.4 
(95% CI 0.1–2.0), P = 0.26 at 6 weeks and 0.5 (95% CI 
0.1–1.6), P = 0.22 at 12 weeks.
Statistically significant between group differences were 
observed for PGI improvement both at 6 weeks (P = 0.001) 
and 12 weeks (P < 0.001) (Table 3). 17% of women in 
the Pelviva group described themselves as feeling very 
much better and a further 54% a little or much better 
after 12 weeks compared to 0% and 15% of women in 
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the control group. After 6 weeks, 52% of women in the 
Pelviva group were already feeling a little or much better 
compared to 14% in the control group. 3% of women in 
the Pelviva and 15% in the TAU groups described their 
condition as worsening.
Sexual health impact
The FSFI showed no statistically significant between 
group difference for either sexually active or non-active 
after 12 weeks. Both trial groups demonstrated an overall 
mean improvement 1.6 points for the control group com-
pared to 2.6 for the Pelviva group (Table 4). No signifi-
cant difference was seen between groups, whether sexually 
active or not in any individual domain (P > 0.12). No sig-
nificant differences were seen at the 6-week mid-treatment 
assessment.
The PISQ-IR followed a similar trend, though between 
group comparison in overall improvement reached statis-
tical significance (P = 0.032). This seemed to be related 
to overall impact of the condition (P = 0.027) rather than 
any specific aspect of sexual activity i.e. desire, arousal/
Fig. 1  Consort diagram—sum-
mary of participant flow
Table 1  Patient characteristics
Participant characteristics for all randomised women and women 
included in the primary analysis
All randomised Analysis dataset
TAU Pelviva TAU Pelviva
Type of incontinence
 Urgency 0/42 (0%) 1/44 (2%) 0/33 (0%) 1/30 (3%)
 Stress 16/42 (38%) 11/44 (25%) 14/33 (42%) 9/30 (30%)
 Mixed 26/42 (62%) 32/44 (73%) 19/33 (58%) 20/30 (67%)
Severity of incontinence (Pad test)
 Mild 31/42 (74%) 29/44 (66%) 26/33 (79%) 21/30 (70%)
 Moderate 9/42 (21%) 11/44 (25%) 6/33 (18%) 7/30 (23%)















26/28 (93%) 24/30 (80%) 24/26 (92%) 17/21 (81%)
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orgasm, condition specific or global quality though global 
quality showed almost as big an effect size as impact 
(Table 4). These improvements were not reported at the 
6-week assessment.
Adverse events
Three adverse events were reported for the Pelviva group 
only. Two related to discomfort when using the device and 
one related to post-menopausal bleeding considered not be 
related to the device.
Effect of participant age
Stratifying the participants by age, those aged < 50 showed 
a stronger treatment response of − 2.59 points (95% CI 
− 4.65 to − 0.53) on the primary ICIQ outcome compared 
to those aged ≥ 50 who showed a − 0.60 point (− 3.53 to 
− 2.34) treatment effect. However, a formal interaction 
test did not show that this difference was statistically sig-
nificant (P = 0.31).
Discussion
General findings
This study took place in a regular GP environment with out-
come data collected on-line and in the privacy of the par-
ticipants own home, a pragmatic ‘real world’ study. It was 
anticipated normal GP care at recruitment would be multi-
faceted, but in practice, only 21–27% received pelvic floor 
exercise advice from the GP or a nurse and the remainder 
received little or no intervention. This does not correspond 
with the NICE (2019) guidelines [10] which recommend 
supervised pelvic floor muscle exercises for at least 3 months 
for stress urinary incontinence and at least 6 weeks of blad-
der retraining for urgency urinary incontinence.
Table 2  ICIQ-UI results
Results for ICIQ-UI total score (primary outcome) and subscales at the primary 12-week assessment point. Values are mean (SD). The effect 
size is the difference in outcome between arms adjusted for baseline and type of incontinence with 95% CI and associated significance level
Outcome Arm Baseline 12-week follow-up Change Pelviva effect (95% CI) P
ICIQ-UI TAU (N = 33) 9.4 (3.9) 8.5 (3.8) − 0.8 (2.1)
Pelviva (N = 30) 11.7 (4.2) 8.5 (4.9) − 3.2 (4.2) − 1.81 (− 3.49 − 0.14) 0.034
Frequency TAU (N = 33) 2.5 (1.3) 2.4 (1.2) − 0.1 (0.9)
Pelviva (N = 30) 3.0 (1.1) 2.3 (1.4) − 0.7 (1.1) − 0.36 (− 0.87 − 0.15) 0.17
Amount TAU (N = 33) 2.5 (0.9) 2.4 (0.8) − 0.1 (1.0)
Pelviva (N = 30) 3.0 (1.0) 2.3 (0.9) − 0.7 (1.1) − 0.24 (− 0.68 − 0.20) 0.28
Interference TAU (N = 33) 4.4 (2.7) 3.8 (2.4) − 0.6 (1.6)
Pelviva (N = 30) 5.7 (2.5) 3.9 (3.0) − 1.9 (2.6) − 0.91 ( − 1.97 − 0.15) 0.092
Fig. 2  ICIQ-UI total score 
(primary outcome) at the two 
assessment times by treatment 
arm. Left hand panel shows the 
actual scores and the right-
hand panel the changes from 
baseline. Boxplots represent 
the median, inter-quartile range 
and absolute range. Means per 
group are shown by points and 
lines
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Interestingly, the extent of intervention remained the 
same during the study for the Pelviva group, but the TAU 
group reported an increase in pelvic floor exercise from 27 
to 64%. It would seem the Pelviva group did not perceive the 
need to change current intervention whilst the TAU group 
appeared more motivated to undertake exercise.
Despite differences in exercise rates, a significant 
improvement in the primary outcome-overall quality of life 
was observed between the Pelviva and control group (three-
point compared to one point, respectively). This corroborates 
with the results from the previous study [three-point, 45% 
improvement vs one-point, 10% for ICIQ-UI (P = 0.014)] 
[9]. The control groups in the previous [9] and current study 
also behaved similarly suggesting little difference between 
GP led intervention or unsupervised pelvic floor exercises.
Improvements in the Pelviva group (1.6 points) were 
evident at 6 weeks suggesting improvement was cumula-
tive over 12 weeks. It is not possible to determine if further 
improvements would have occurred if treatment continued 
beyond 12 weeks due to COVID-19 restrictions. Many clini-
cal studies use 12 weeks as the optimum length of treatment 
though some do use a longer treatment intervention phase of 
up to 6 months [16].
QoL improvements in the Pelviva group were accom-
panied by reports of a global impression of improvement. 
Despite many women describing their incontinence as 
normal or mild when they started treatment, 17% of women 
in the Pelviva group described themselves as feeling very 
much better and a further 54% a little or much better after 
12 weeks. Such improvements were not seen in the control 
group. It is not possible to determine why the Pelviva group 
felt better but women described their incontinence as inter-
fering less in their lives.
Reduction of impact due to Pelviva also translated 
through to sexual health. The psychological effects of incon-
tinence can have a considerable impact on quality of life. 
Women often report low self-esteem, mood changes and 
feelings of helplessness and even anxiety and depression [17, 
18]. It is possible Pelviva offered women hope of improve-
ment and this in turn reduced the psychological impact. It is 
also possible there was a quantitative improvement in vol-
ume of urine loss. It was the intention to monitor this using 
the 1-h pad test but due to COVID-19 this was not possible.
In terms of age, a formal interaction test for a difference 
in Pelviva effect was not significant (P = 0.31), so this study 
cannot conclude that the treatment has different effects in 
younger and older women. The Pelviva effect, however, 
seemed to be larger in the younger women, and whilst this 
could be a chance finding it should be considered further.
Real world study and impact of COVID‑19
A large number of women 13,052 were approached by text 
messaging to participate in this trial and 226 women (1.7%) 
responded. This response rate corresponds with Plante 
et al. [19] who approached 6896 American citizens and 
116 (1.7%) people expressed an interest. Plante et al. also 
described a 10% recruitment rate that was lower than the 86 
women (38%) in the current study. This could be due to the 
GP-led approach adopted for the current study compared to 
an investigator led recruitment suggesting a real-world GP 
approach gives greater assurance and confidence to patients 
and improves recruitment into clinical trials.
More women withdrew in the Pelviva group compared 
to TAU though non-responders were the same for both 
groups. Women who withdrew cited challenges on time and 
other commitments that may have been due to additional 
responsibilities and the impact of COVID-19. Excluding 
non-responders, adherence to Pelviva was 61%. Pelviva 
has been designed to be used in the privacy of the home so 
even in a COVID-19 situation self-treatment could continue 
demonstrating the considerable benefit of such a treatment 
approach.
Limitations of the study
The study was under-powered due to the impact of the 
COVID-19 situation. Furthermore, the 1-h pad test could 
Table 3  PGI results
PGI improvement for the two trial arms at the mid-treatment 
(6-week) and final (12-week) assessment points along with the sig-






 Very much better 1 (3%) 5 (17%)
 Much better 4 (14%) 5 (17%)
 A little better 11 (38%) 11 (37%)
 No change 12 (41%) 8 (27%)
 A little worse 1 (3%) 1 (3%)
 Much worse 0 (0%) 0 (0%)
 Very much worse 0 (0%) 0 (0%)
 Missing 15 (34%) 14 (32%)
TAU 
 Very much better 0 (0%) 0 (0%)
 Much better 0 (0%) 1 (3%)
 A little better 4 (14%) 4 (12%)
 No change 23/29 (79%) 22 (69%)
 A little worse 1 (3%) 4 (12%)
 Much worse 1 (3%) 1 (3%)
 Very much worse 0 (0%) 0 (0%)
 Missing data 13 (31%) 10 (24%)
 P 0.001 < 0.001
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not be completed post-treatment as originally planned. 
Despite these limitations, the results from the first pad test 
showed the majority of women had apparently mild prob-
lems whilst responses for ICIQ covered the whole range of 
the scale (0–21) except for the very low end. The correla-
tion between ICIQ and pad test responses was rather weak 
(  = 0.35 for ICIQ total and 0.19 for amount). This would 
suggest that the 1-h test is not correlated with patients’ 
daily activities, has poor-to-moderate sensitivity and ques-
tions the validity of adopting the test in a Primary Care 
population with a self-administered treatment and real-
world evaluation. In addition, it was not possible to blind 
patients to treatment group as the study was deliberately 
designed to test Pelviva against current GP practice and, 
therefore, not to incorporate a sham group.
Conclusion
This study has demonstrated that Pelviva is a successful 
adjunct to GP prescribed care for the treatment of female 
urinary incontinence. Statistically significant superior results 
were seen in relation to overall quality of life, interference 
with life and impact on sexual health. These results were 
observed despite early termination of this study due to 
COVID-19 and a considerably reduced sample size. The 
study also highlighted some limitations of the 1-h pad test 
when assessing severity of urine loss.
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Table 4  FSFI and PISQ-IR results
Results for FSFI and PISQ-IR total score in sexually active and inactive women at the primary 12-week assessment point. Values are mean (SD). 
The effect size is the difference in outcome between arms adjusted for baseline and type of incontinence with 95% CI and associated significance 
level
Outcome Arm Baseline Follow-up Change Treatment effect P
FSFI-sexually active
 Overall score TAU (N = 18) 25.3 (6.0) 26.9(5.0) 1.6 (2.8)
Pelviva (N = 22) 25.1 (6.9) 27.7(7.0) 2.6 (5.2) 0.98 (− 1.79 − 3.75) 0.48
FSFI score—Inactive
TAU (N = 5) 2.6 (1.5) 2.5 (1.0) − 0.1 (1.1)
Pelviva (N = 4) 1.8 (1.2) 2.2 (1.2) 0.4 (0.9) 0.16 (− 1.56 − 1.87) 0.82
PISQ-IR Sexually active
 Overall score TAU (N = 21) 2.9 (0.4) 3.0 (0.5) 0.0 (0.3)
Pelviva (N = 20) 2.9 (0.4) 3.1 (0.4) 0.2 (0.4) 0.21 (0.02 − 0.40) 0.032
 Desire TAU (N = 21) 2.9 (0.7) 2.9 (0.8) − 0.0 (0.4)
Pelviva (N = 20) 3.1 (0.7) 3.2 (0.6) 0.1 (0.6) 0.13 (− 0.18 − 0.44) 0.41
 Arousal/orgasm TAU (N = 21) 3.3 (0.7) 3.5 (0.7) 0.2 (0.3)
Pelviva (N = 20) 3.5 (0.7) 3.8 (0.8) 0.3 (0.7) 0.15 (− 0.17 − 0.48) 0.35
 Condition specific TAU (N = 21) 1.8 (0.9) 1.7 (0.8) − 0.1 (0.7)
Pelviva (N = 20) 1.7 (0.9) 1.5 (0.6) − 0.2 (0.8) − 0.21 (− 0.57 − 0.14) 0.23
 Global quality TAU (N = 21) 3.2 (1.0) 3.4 (1.1) 0.2 (0.6)
Pelviva (N = 20) 2.9 (0.9) 3.5 (0.9) 0.6 (1.0) 0.36 (− 0.12 − 0.84) 0.14
 Condition impact TAU (N = 21) 3.1 (0.9) 3.2 (0.8) 0.1 (0.6)
Pelviva (N = 20) 2.9 (1.0) 3.4 (0.7) 0.5 (0.8) 0.39 (0.05 − 0.74) 0.027
PISQ-IR sexually inactive
 Partner-related TAU (N = 4) 3.0 (1.4) 2.8 (1.1) − 0.2 (0.5)
Pelviva (N = 6) 2.8 (2.0) 2.8 (2.0) 0.0 (0.0) 0.18 (− 0.43 − 0.78) 0.49
 Condition specific TAU (N = 4) 3.9 (0.3) 3.5 (0.4) − 0.4 (0.4)
Pelviva (N = 6) 3.3 (0.8) 3.7 (0.4) 0.3 (0.5) 0.40 (− 0.10 − 0.89) 0.096
 Quality TAU (N = 4) 2.0 (1.2) 2.2 (1.2) 0.2 (0.8)
Pelviva (N = 6) 2.5 (0.0) 2.5 (1.2) 0.0 (1.2) − 0.10 (− 2.11 − 1.91) 0.90
 Condition impact TAU (N = 4) 3.9 (0.3) 3.5 (0.4) − 0.4 (0.4)
Pelviva (N = 6) 3.3 (0.8) 3.7 (0.4) 0.3 (0.5) 0.40 (− 0.10 − 0.89) 0.096
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